A Prospective, Open-Label, Non-Randomized, Multi-Center Study To Investigate The Safety And Tolerability Of Voriconazole As Primary Therapy For Treatment Of Invasive Aspergillosis And Molds Such As Scedosporium Or Fusarium Species In Pediatric Patients

Trial Profile

A Prospective, Open-Label, Non-Randomized, Multi-Center Study To Investigate The Safety And Tolerability Of Voriconazole As Primary Therapy For Treatment Of Invasive Aspergillosis And Molds Such As Scedosporium Or Fusarium Species In Pediatric Patients

Discontinued
Phase of Trial: Phase III

Latest Information Update: 22 Jun 2017

At a glance

  • Drugs Voriconazole (Primary)
  • Indications Aspergillosis
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 18 Oct 2016 New trial record
    • 15 Sep 2016 Results assessing safety and efficacy outcomes of Voriconzaole in pediatric patients from NCT01092832 and NCT00836875 studies ,published in the Pediatric Infectious Disease Journal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top